A Study of BRY805 in Participants With Advanced Solid Tumors - Trial NCT06289894
Access comprehensive clinical trial information for NCT06289894 through Pure Global AI's free database. This Phase 1 trial is sponsored by BioRay Pharmaceutical Co., Ltd. and is currently Not yet recruiting. The study focuses on Advanced Solid Tumor. Target enrollment is 30 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
BioRay Pharmaceutical Co., Ltd.
Timeline & Enrollment
Phase 1
Mar 01, 2024
Sep 01, 2027
Primary Outcome
Occurrence of Drug Limited Toxicities (DLTs),Type and incidence of Treatment-emergent adverse event (TEAEs) and serious adverse events (SAEs)
Summary
This is a phase 1 open label multicenter study to evaluate safety, tolerance and the maximum
 tolerance of BRY805 administered intravenously (IV) once every three weeks in participants
 with advanced solid tumors, so as to confirm the recommended phase 2 dose of BRY805 and
 obtain the preliminary efficacy information of participants with advanced solid tumors.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06289894
Non-Device Trial